中文傳媒(600373.SH):智明星通擬認購5000萬元挑戰者文創份額 出資總比例20%
格隆匯7月7日丨中文傳媒(600373.SH)公佈,為進一步佈局遊戲產業,公司控股子公司北京智明星通科技股份有限公司(以下簡稱“智明星通”)擬作為有限合夥人,以自有資認購廈門挑戰者文創創業投資合夥企業(有限合夥)的新增出資份額人民幣5000萬元。
挑戰者文創成立於2020年6月5日,主要投資於遊戲行業的成長期公司,預計募集總規模為人民幣2.5億元,已募集規模為人民幣1.5億元,智明星通擬作為有限合夥人以自有資金認繳新增的出資份額人民幣5000萬元,出資總比例為20.00%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.